The Analgesic Efficacy of Lidocaine/Prilocaine (EMLA) cream during Dry Needling of an Active Myofascial Trigger Point in the Upper Trapezius Muscle: A Double-blind Randomized Controlled Trial

Start Date04 Jul 2023

Sponsor / Collaborator

Phramongkutklao Hospital

100 Clinical Results associated with Phramongkutklao Hospital

0 Patents (Medical) associated with Phramongkutklao Hospital

769

Literatures (Medical) associated with Phramongkutklao Hospital

31 Dec 2024·Journal of Pharmaceutical Policy and Practice

Expert consensus guidelines for community pharmacists in the management of diabetic peripheral neuropathy with a combination of neurotropic B vitamins

Review

Author: Sathienluckana, Thanompong ; Suksomboon, Naeti ; Yotsombut, Kitiyot ; Wanothayaroj, Ekgaluck ; Sithinamsuwan, Pasiri ; Palapinyo, Sirinoot

This consensus guidance is for community pharmacists in diabetic peripheral neuropathy (DPN) management with a combination of neurotropic B vitamins. A multidisciplinary team including endocrinology, neurology, and pharmacy from Thailand discussed and aligned the practical scheme of DPN management in the community pharmacy setting, using the literature review and having face-to-face meeting. Five major statements have been endorsed as consensus recommendations for DPN care with strong acknowledgment. The aims of DPN management included reducing symptoms and the risk of complications, minimising adverse reactions from treatment regimens, and improving patients' knowledge and adherence to the treatment strategies. An initial screening process using a 7 items interview of Douleur Neuropathique 4 (DN4) questionnaire should be implemented to identify patients at risk of developing DPN. Subsequently, pharmacologic, and non-pharmacologic treatment should be employed based on patient-centered care. An interesting approach is combination of neurotropic B vitamins, which may be used as monotherapy or combination therapy to control DPN symptoms. The combined therapy potentially exhibits a synergistic effect and improves patient adherence. The consensus would be further considered in context of harmonisation of routine practice and country requirements.

01 Nov 2024·Journal of the Neurological Sciences

Perampanel for the treatment of Asian people with epilepsy: Real-world evidence from the PERMIT extension study

Article

Author: Alsaadi, Taoufik ; Villanueva, Vicente ; Wu, Tony ; Goji, Hiroko ; Chinvarun, Yotin ; Dash, Amitabh ; Kanemoto, Kousuke ; Cappucci, Sheri ; Kim, Dong Wook

This post-hoc analysis of the PERMIT Extension study compared the effectiveness and safety/tolerability of perampanel (PER) between Asian and non-Asian participants. Retention rates, adverse events (AEs), seizure frequency, responder rate (≥50% seizure frequency reduction), and seizure freedom rate (no seizures since at least the prior visit) were assessed. Retention was assessed after 3, 6 and 12 months. Effectiveness assessments were evaluated at 3, 6 and 12 months and the last visit by seizure type (total, focal and generalised). PERMIT Extension included 730 Asian and 1662 non-Asian individuals. Significant differences in demographic/baseline characteristics were reported for the Asian versus non-Asian subgroups including higher median age at epilepsy onset, longer median duration of epilepsy, higher mean number of previous and concomitant ASMs and lower mean monthly seizure frequency (total, focal and generalised). Retention rates were similar between the two subgroups at 3 and 12 months, but significantly lower in the Asian versus non-Asian subgroup at 6 months (65.6% vs. 71.8%; p = 0.004). At last visit, seizure freedom rate was significantly higher in the Asian versus non-Asian for total (35.9% vs. 25.4%; p = 0.001) and focal seizures (32.4% vs. 18.9%; p = 0.001) as was responder rate for both total (63.9% vs. 52.3%; p = 0.001) and focal seizures (62.2% vs. 44.7%; p < 0.001). Seizure freedom and responder rates for generalised seizures were similar between the two subgroups at the last visit. Rates of AEs were similar between the two subgroups (Asian, 47.6%; non-Asian, 45.4%). PER was effective and generally well-tolerated in Asian and non-Asian individuals.

01 Sep 2024·International Journal of Cardiology

Reassessing heart failure therapy in Thailand: Patient insights and treatment outcomes from the Thai heart failure registry

Article

Author: Ratanasumawong, Kasem ; Senthong, Vichai ; Charoenyos, Noppawan ; Chirakarnjanakorn, Srisakul ; Chantrarat, Thoranis ; Buakhamsri, Adisai ; Chotenimitkhun, Runyawan ; Kunjara-Na-Ayudhya, Rapeephon ; Phrommintikul, Arintaya ; Wongtheptien, Wattana ; Yingchoncharoen, Teerapat ; Thundee, Chalongchai ; Ariyachaipanich, Aekarach ; Krittayaphong, Rungroj ; Sethalao, Porntera ; Songmuang, Smonporn Boonyaratavej ; Chichareon, Ply ; Puwanant, Sarinya ; Kanjanavanich, Rungsrit ; Boonyapiphat, Thanita

BACKGROUNDThis research analyzed the demographics, management, and outcomes of patients with heart failure (HF) in Thailand.METHODSThe Thai Heart Failure Registry prospectively enrolled patients diagnosed with HF from 36 hospitals in Thailand. Follow-up data were recorded at 6, 12, 18, and 24 months. This study primarily focused on two outcomes: mortality and HF-related hospitalizations.RESULTSThe study included 2639 patients aged at least 18. Their mean age was 59.2 ± 14.5 years, and most were male (68.4%). Patients were classified as having HF with reduced ejection fraction (HFrEF, 80.7%), HF with preserved ejection fraction (HFpEF, 9.0%), or HF with mildly reduced ejection fraction (HFmrEF, 10.3%). Guideline-directed medical therapy utilization varied. Beta-blockers had the highest usage (93.2%), followed by mineralocorticoid receptor antagonists (65.7%), angiotensin-converting enzyme inhibitors (39.3%), angiotensin receptor blockers (28.2%), angiotensin receptor-neprilysin inhibitors (16.1%), and sodium-glucose cotransporter-2 inhibitors (8.0%). The study monitored a composite of mortality and HF incidents, revealing incidence rates of 11.74, 12.50, and 8.93 per 100 person-years for the overall, HFrEF, and HFmrEF/HFpEF populations, respectively.CONCLUSIONSDespite high guideline-directed medical therapy adherence, the Thai Heart Failure Registry data revealed high mortality and recurrent HF rates. These findings underscore limitations in current HF treatment efficacy. The results indicate the need for further investigation and improvements of HF management to enhance patient outcomes.

100 Deals associated with Phramongkutklao Hospital

100 Translational Medicine associated with Phramongkutklao Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 25 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Phramongkutklao Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 25 Nov 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing